Meta-analysis of two randomized phase III trials (TCOG GI-0801 and ECRIN TRICS) of biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer

Background Biweekly irinotecan (CPT-11) plus cisplatin (CDDP) combination (BIRIP) and CPT-11 alone are both expectable options for treating advanced gastric cancer (AGC) in a second-line setting. We conducted a meta-analysis to compare the efficacy and safety of these two regimens in patients enroll...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2020, Vol.23 (1), p.160-167
Hauptverfasser:	Nishikawa, Kazuhiro, Koizumi, Wasaburo, Tsuburaya, Akira, Yamanaka, Takeharu, Morita, Satoshi, Fujitani, Kazumasa, Akamaru, Yusuke, Shimada, Ken, Hosaka, Hisashi, Nakayama, Norisuke, Tsujinaka, Toshimasa, Sakamoto, Junichi
Format:	Artikel
Sprache:	eng
Schlagworte:	Abdominal Surgery Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer Research Chemotherapy Cisplatin Cisplatin - administration & dosage Clinical trials Clinical Trials, Phase III as Topic Disease control Female Gastric cancer Gastroenterology Humans Irinotecan Irinotecan - administration & dosage Male Medicine Medicine & Public Health Meta-analysis Middle Aged Oncology Original Article Patients Randomized Controlled Trials as Topic Stomach Neoplasms - drug therapy Stomach Neoplasms - mortality Surgical Oncology Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!